Outpatient ulcerative colitis primary anti-TNF responders receiving adalimumab or infliximab maintenance therapy have similar rates of secondary loss of response

Journal of Clinical Gastroenterology

Volumn 49, Issue 8, 2015, Pages 675-682

  Ma, Christopher ^a   Huang, Vivian ^a   Fedorak, Darryl K ^a   Kroeker, Karen I ^a   Dieleman, Levinus A ^a   Halloran, Brendan P ^a   Fedorak, Richard N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adalimumab; Dose escalation; Infliximab; Secondary loss of response; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ALBUMIN; AZATHIOPRINE; C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; INFLIXIMAB; MESALAZINE; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; COHORT ANALYSIS; COLON RESECTION; COLON SURGERY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PANCOLITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY LOSS OF RESPONSE; SMOKING; TREATMENT RESPONSE; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE; COMPARATIVE STUDY; FOLLOW UP; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; TIME FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

ADALIMUMAB; ADULT; ANTI-INFLAMMATORY AGENTS; COHORT STUDIES; COLITIS, ULCERATIVE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OUTPATIENTS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84942515113     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000265     Document Type: Article

References (26)

1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627-1640.
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
3. Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18:201-211.
4. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780-787.
5. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012; 142:257.e1-3-265.e1-3.
6. Armuzzi A, Pugliese D, Nardone OM, et al. Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab. Drug Des Devel Ther. 2013;7:289-296.
7. Trinder MW, Lawrance IC. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol. 2009;24:1252-1257.
8. Barreiro-de Acosta M, Lorenzo A, Dominguez-Munoz JE. Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years. World J Gastroenterol. 2009;15:3814-3816.
9. Afif W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009;15:1302-1307.
10. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
11. Rostholder E, Ahmed A, Cheifetz AS, et al. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther. 2012;35:562-567.
12. McDermott E, Murphy S, Keegan D, et al. Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis. J Crohns Colitis. 2013;7:150-153.
13. Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660-1666.
14. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990.
15. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753.
16. Danese S. Adalimumab in ulcerative colitis: ready for prime time. Dig Liver Dis. 2013;45:8-13.
17. Reinisch W, Sandborn WJ, Panaccione R, et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis. 2013;19:1700-1709.
18. Armuzzi A, Biancone L, Daperno M, et al. Italian Group for the Study of Inflammatory Bowel Disease. Adalimumab in active ulcerative colitis: a "real-life" observational study. Dig Liver Dis. 2013;45:738-743.
19. Kestens C, van Oijen MG, Mulder CL, et al. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-alpha agents. Clin Gastroenterol Hepatol. 2013;11:826-831.
20. Gies N, Kroeker KI, Wong K, et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther. 2010;32:522-528.
21. Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther. 2008;28:966-972.
22. Peyrin-Biroulet L, Laclotte C, Roblin X, et al. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol. 2007;13:2328-2332.
23. Taxonera C, Estelles J, Fernandez-Blanco I, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther. 2011;33:340-348.
24. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
25. Ma C, Huang V, Fedorak DK, et al. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study. J Crohns Colitis. 2014;8: 1454-1463.
26. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392.e3-400.e3.